CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• CDKL5 deficiency disorder (CDD) is an X-linked neurodevelopmental disorder caused by pathogenic variants in the CDKL5 gene.
• CDD presents in early childhood with infantile onset, intractable seizures, and severe cognitive and motor impairments.
• The CDKL5 protein, a kinase, plays a critical role in neuronal development by regulating phosphorylation events essential for neural network formation.

Purpose of the Study:

• To summarize recent findings on the function of the CDKL5 protein.
• To elucidate CDKL5 phosphorylation targets and the impact of their disruption on human brain signaling pathways.
• To highlight how this knowledge can advance drug discovery for CDD.

Main Methods:

• Review of current literature on CDKL5 protein function.
• Analysis of identified CDKL5 phosphorylation targets.
• Examination of signaling pathway disruptions in the human brain due to CDKL5 variants.

Main Results:

• New insights into CDKL5 phosphorylation targets have been identified.
• The consequences of CDKL5 dysfunction on key signaling pathways in the human brain are better understood.
• Understanding CDKL5 biology provides a foundation for therapeutic development.

Conclusions:

• Advances in understanding CDKL5 biology are essential for developing targeted therapies for CDD.
• Leveraging new knowledge of CDKL5 function can accelerate drug discovery and treatment development.
• Further development of humanized models is critical for testing potential CDD therapies.